TEST:

C2inform test

"OncoDNA...announced the next stage in its partnership with C2i Genomics...The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test."

"C2i Genomics...announced its strategic collaboration with the Tel Aviv Sourasky Medical Center (Ichilov)...Together, the organizations will provide precision oncology clinical testing using C2inform, C2i Genomics’ whole genome minimal residual disease (MRD) test to improve cancer detection and monitoring nationwide."

Our results highlight the clinical potential of personalized genome-wide mutation integration as an ultra-sensitive, non-invasive method for MRD detection and treatment response monitoring.

C2inform showed great inter-lab reproducibility and enabled prediction of recurrence after treatment and during surveillance. Thus, C2inform has the potential to guide clinical decision-making during the postoperative management of CRC patients.

"US-headquartered startup C2i Genomics has announced a collaboration with Riken Genesis (RG) Co. to bring minimal residual disease (MRD) cancer monitoring to Japan for pharmaceutical and clinical research...Under this agreement, RG will work with C2i Genomics to commercialise its C2intelligence cloud-based platform and the C2inform MRD test for pharmaceutical and clinical research and eventually for commercial clinical testing in Japan."

"AstraZeneca will evaluate C2i Genomics' whole-genome minimal residual disease assay and cancer-monitoring platform for use in clinical research and drug development efforts, the companies announced Thursday...The agreement is an extension of a previous collaboration in which the companies evaluated C2i Genomics' minimal residual disease (MRD) test across multiple solid cancers using artificially generated samples. The test was able to detect circulating tumor DNA (ctDNA), which was present at varying levels in the samples, down to 0.002 percent allelic frequency, the firms said."

"C2i Genomics...announced it has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU and UK. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore."